BioMarin Pharmaceuticals 8-K Report: Key Corporate Developments Unveiled
Based on the provided excerpt from the financial report, here are the key insights and information extracted:
- Entity Information:
- Company Name: BioMarin Pharmaceutical Inc.
- CIK (Central Index Key): 0001048477
- State of Incorporation: Delaware (DE)
- SEC File Number: 000-26727
- Employer Identification Number (EIN): 68-0397820
- Address: 770 Lindaro Street, San Rafael, CA 94901
- Contact Number: 415-506-6700
- Filing Information:
- Filing Type: 8-K (a report of unscheduled material events or corporate changes)
- Filing Date: February 19, 2025
- Stock Information:
- Common Stock: Par value of $0.001
- Ticker Symbol: BMRN
- Exchange: NASDAQ
- Period of Reporting:
- Start Date: February 19, 2025
- End Date: February 19, 2025
Insights:
- The document indicates a significant corporate event or development requiring disclosure, as implied by the 8-K filing.
- BioMarin Pharmaceutical is actively listed on NASDAQ, which suggests it is a publicly traded company and subject to SEC regulations and disclosures.
- Given the report's focus on a single day, it may relate to a specific event or announcement that occurred on that date, warranting further examination of the details surrounding this 8-K filing for implications on the company’s operations or stock performance.
This summary encapsulates the essential details and context of the filing while hinting at the potential significance of the reported event.